Health Catalyst, Inc.

NASDAQ:HCAT

Medical - Healthcare Information Services

Healthcare
$1.29 -1.98%

-$0.04 today

Market cap
$98.24M
Beta
1.66
P/E (TTM)
-0.5
EPS (TTM)
-$3.65
52W Low $0.96High $4.13

Volume 0.27M

Average 1.24M

HCAT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Health Catalyst, Inc.NASDAQ: HCAT

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$93.76M, compared with -$3.89M a year earlier. Trailing-twelve-month EBITDA was -$192.37M.

Context

  • EBITDA amounted to 35.5% of revenue in FY2025, up 32.0 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of $52.72M (+147.8%) for the fiscal year ending Dec 2026, a step up from the -936.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$93.76M-29.8% QoQ
Last fiscal yearDec 2025
-$110.35M-936.0% YoY
LTMMar 2026
-$192.37M-1267.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2309.5%+182.5%+2492.0 pp
1 year-936.0%+147.8%+1083.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(110.35M) USD
Year-over-year change
-936.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How HCAT compares with its peers on the latest reported figures

  • HCAT's LTM Mar 2026 EBITDA of -$192.37M is the lowest of the 11 companies compared; the peer median is -$68.91M.
  • Its year-over-year change of -1267.9% is the lowest of 11, against a peer median of +22.0%.
  • EBITDA amounts to 63.6% of revenue for HCAT, versus a peer median of 415.8%.
HCAT Competitors Peer median
EBITDA for HCAT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNWVSANUWAVE Health, Inc.LTM Mar 2026$22.67M +217.1%+59.4%51.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$46.56M +46.6%—67.3%
NNOXNano-X Imaging Ltd.LTM Dec 2025-$49M -11.0%—376.3%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$52.72M +20.1%—161.1%
OMOutset Medical, Inc.LTM Mar 2026-$62.35M +22.0%—53.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$75.47M +22.0%—33540.9%
PYXSPyxis Oncology, Inc.LTM Mar 2026-$75.93M +0.5%—547.9%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-$76.13M +39.6%—455.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$111.97M +23.4%—999.5%
HSDTSolana CompanyLTM Mar 2026-$135.55M -1012.4%—1413.6%
HCATHealth Catalyst, Inc.LTM Mar 2026-$192.37M -1267.9%—63.6%
Peer median (excluding HCAT) -$68.91M+22.0%+59.4%415.8%

Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue241.93M276.24M295.94M306.58M311.14M
Cost of Revenue124.35M143.05M164.11M165.81M207M
Gross Profit117.57M133.19M131.83M140.78M104.13M
Gross Margin48.6%48.2%44.5%45.9%33.5%
Research & Development62.73M75.68M72.63M57.95M49.77M
Selling, General & Admin160.96M149.22M143.88M111.2M102.04M
Operating Expenses261.22M273.19M258.73M210.59M140.24M
Depreciation & Amortization41.11M51.53M42.22M41.43M50.5M
EBITDA(101.68M)(82.92M)(68.28M)(10.65M)(110.35M)
EBITDA Margin-42.0%-30.0%-23.1%-3.5%-35.5%
Operating Income(143.65M)(140.01M)(126.9M)(69.81M)(36.1M)
Operating Margin-59.4%-50.7%-42.9%-22.8%-11.6%
Interest Income831K5.69M16.39M17.98M7.54M
Interest Expense17.31M7.24M7.29M17.09M16.4M
Other Income / Expenses(16.46M)(1.68M)9.11M637K(141.15M)
Income Before Tax(160.11M)(141.68M)(117.79M)(69.17M)(177.26M)
Pre-Tax Margin-66.2%-51.3%-39.8%-22.6%-57.0%
Income Tax Expense(6.9M)(4.28M)356K333K716K
Net Income(153.21M)(137.4M)(118.15M)(69.5M)(177.97M)
Net Margin-63.3%-49.7%-39.9%-22.7%-57.2%
EPS (Basic)(3.23)(2.56)(2.09)(1.15)(2.55)
EPS (Diluted)(3.23)(2.54)(2.09)(1.15)(2.55)
Weighted Avg Shares47.49M53.72M56.42M60.19M69.9M
Weighted Avg Shares (Diluted)47.49M54.08M56.42M60.19M69.9M

Health Catalyst, Inc.

NASDAQ:HCAT

Intrinsic Alpha fair value

Locked

Current Price

$1.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.